ArticleFrontiers in neuroscience2021
Boldine Attenuates Synaptic Failure and Mitochondrial Deregulation in Cellular Models of Alzheimer's Disease.
Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Boldine Mitigates Chronic Unpredictable Stress-Induced Depression by Suppressing Serotonin 3A Receptor-Calcium/Calmodulin-Dependent Protein Kinase II Signaling and Nucleotide-Binding Domain Leucine-Rich Repeat Protein 3 Inflammasome in the Hippocampus.ACS pharmacology & translational science · 2026Article
- Oral administration of boldine reduces neuropathic pain After spared nerve injury in female mice.Pain reports · 2026Article
- Effects of selected alkaloids on postnatal neurogenesis - in vivo and in vitro studies - literature review.Psychopharmacology · 2025Review
- Cordycepin mediates neuroprotection against apoptosis via ERK/CREB signaling activation in AβIbrain · 2025Article
- Article
- Pharmacology of boldine: summary of the field and update on recent advances.Frontiers in pharmacology · 2024Review
- An Overview of Chemistry, Kinetics, Toxicity and Therapeutic Potential of Boldine in Neurological Disorders.Neurochemical research · 2023Review
- Computer Aided Drug Design Methodologies with Natural Products in the Drug Research Against Alzheimer's Disease.Current neuropharmacology · 2022Review
- Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome.Molecules (Basel, Switzerland) · 2021Review
- Analysis of comorbid characteristics, molecular mechanisms between mild cognitive impairment and Alzheimer's disease with interventions in a community-based population in Shanghai.Frontiers in neurologyArticle
- Complementary and Alternative Medicine Approaches in Alzheimer Disease and Other Neurocognitive Disorders.Missouri medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common cause of senile dementia worldwide, characterized by both cognitive and behavioral deficits. Amyloid beta peptide (Aβ) oligomers (AβO) have been found to be responsible for several pathological mechanisms during the development of AD, including altered cellular homeostasis and synaptic function, inevitably leading to cell death. Such AβO deleterious effects provide a way for identifying new molecules with potential anti-AD properties. Available treatments minimally improve AD symptoms and do not extensively target intracellular pathways affected by AβO. Naturally-derived compounds have been proposed as potential modifiers of Aβ-induced neurodysfunction and cytotoxicity based on their availability and chemical diversity. Thus, the aim of this study was to evaluate boldine, an alkaloid derived from the bark and leaves of the Chilean tree
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.